This article was originally published in HCPLive® and has been lightly edited. The risk of fractures is almost doubled for individuals with acute calcium pyrophosphate crystal arthritis compared to ...

Philadelphia, May 28, 2025 – In a first-of-its-kind genome-wide association study (GWAS) researchers have discovered two genes, RNF144B and ENPP1, that cause calcium pyrophosphate deposition (CPPD) ...

Patients with calcium pyrophosphate deposition (CPPD) disease, also known as pseudogout, have an 80% higher risk for fracture than individuals who do not have the disease, according to a new analysis.

ATLANTA - Researchers will present the first-ever study of fractures and calcium pyrophosphate deposition disease at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SAN DIEGO — Patients with acute calcium pyrophosphate ...

Calcium pyrophosphate deposition disease (CPPD) is a form of arthritis characterised by the accumulation of calcium pyrophosphate crystals within the joint cartilage and surrounding tissues. This ...

Calcium pyrophosphate deposition disease (CPPD), or pseudogout, is one of the most common forms of inflammatory arthritis in individuals over 60 years of age and is characterized by the deposition of ...

Crowned dens syndrome (CDS) is a clinical entity primarily characterised by acute neck pain and stiffness resulting from calcific deposits that form a distinctive crown‐like pattern around the ...

In a first-of-its-kind genome-wide association study (GWAS) researchers have discovered two genes, RNF144B and ENPP1, that cause calcium pyrophosphate deposition (CPPD) disease in Americans of ...

Researchers will present the first-ever study of fractures and calcium pyrophosphate deposition disease at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting. They ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.